Occurrence of Bronchiolitis Obliterans Organizing Pneumonia with the Use of Temozolomide Chemotherapy: A Case Report

Vamsidhar Vennamaneni¹, Raul Fernandez¹, Rishbha Dua^1, , George Michel¹, Virendrasinh Ravat¹ and George Yatzkan¹

¹Department of Internal Medicine, Larkin Community Hospital, 7031 SW 62nd Ave, South Miami, FL 33143

Cite this paper:
Vamsidhar Vennamaneni, Raul Fernandez, Rishbha Dua, George Michel, Virendrasinh Ravat and George Yatzkan. Occurrence of Bronchiolitis Obliterans Organizing Pneumonia with the Use of Temozolomide Chemotherapy: A Case Report. American Journal of Medical Case Reports. 2022; 10(11):286-290. doi: 10.12691/ajmcr-10-11-2

Abstract

Bronchiolitis Obliterans Organizing Pneumonia (BOOP), also known as Cryptogenic Organizing Pneumonia, is an uncommon disease defined as an inflammation of the bronchioles which resembles pneumonia on imaging but it is in fact non-infectious pneumonia. BOOP associated with Temozolomide has been observed in a few patients and documented very little, hence, internists and oncologists at the frontier of care must be aware of this lung damage. Here we present a case of a 67-year-old patient who presents with bronchiolitis obliterans organizing pneumonia after receiving chemotherapy for Glioblastoma Multiforme with Temozolomide. When discovering the trigger for the illness was Temozolomide, it was promptly discontinued, and treatment with methylprednisolone was promptly initiated, which provided significant improvement.

Keywords:
Bronchiolitis Obliterans Organizing Pneumonia (BOOP) cryptogenic organizing pneumonia non-infectious pneumonia Temozolomide Glioblastoma Multiforme

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Tae-Ok, Kim-In-Jae, Oh-Hyun-Wook, et al.: Temozolomide-associated Bronchiolitis Obliterans Organizing Pneumonia Successfully Treated with High-dose Corticosteroid https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314861/J Korean Med Sci. 2012, 27: 450-453.
[2]	LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Temozolomide. [Updated 2020 Sep 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548816/.
[3]	Colvin M. Alkylating agents and platinum antitumor compounds. In: Kufe DW, Frei E, Holland JF, et al, eds. Holland-Frei Cancer Medicine. 8th ed. Shelton, Connecticut: People’s Medical Publishing House; 2010.
[4]	Cazzato S, Zompatori M, Baruzzi G, et al.: Bronchiolitis obliterans-organizing pneumonia: an Italian experience. Respir Med. 2000, 94: 702-8.
[5]	Danson SJ, Middleton MR: Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001, 1: 13-9.
[6]	Duane S Pinto. (2022). Accessed: 06/2022: https://www.uptodate.com/contents/pathophysiology-of-cardiogenic-pulmonary-edema.
[7]	Stover DE, Mangino D: Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia?. Chest. 2005, 128: 3611-7.
[8]	Poletti V, Cazzato S, Minicuci N, Zompatori M, Burzi M, Schiattone ML: The diagnostic value of bronchoalveolar lavage and transbronchial lung biopsy in cryptogenic organizing pneumonia. Eur Respir J. 1996, 9: 2513-6.
[9]	Chandra D, Maini R, Hershberger DM: Cryptogenic Organizing Pneumonia. [Updated 2021 Sep 18]. In. StatPearls [Internet, Treasure Island (FL): StatPearls Publishing; 2022.
[10]	Al-Ghanem S, Al-Jahdali H, Bamefleh H, Khan AN: Bronchiolitis obliterans organizing pneumonia: pathogenesis, clinical features, imaging and therapy review. Ann Thorac Med. 2008, 3: 67-75.
[11]	Radzikowska E, Wiatr E, Langfort R, et al.: Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. PLoS One. 2017, 25:0184739.
[12]	Watanabe K, Senju S, Wen FQ, Shirakusa T, Maeda F, Yoshida M: Factors related to the relapse of bronchiolitis obliterans organizing pneumonia. Chest. 1998, 114:1599-606.